WuXi PharmaTech and Mayo Clinic-backed anti-ageing disease therapy developer Unity Biotechnology has secured series C funding to take its total equity financing to more than $200m.
Unity Biotechnology, a US-based developer of therapies for age-related conditions, closed a $55m series C round on Monday featuring 6 Dimensions Capital, the investment vehicle co-founded by pharmaceutical firm WuXi PharmaTech.
Financial services and investment group Fidelity Management and Research (FMR) also contributed to the round, as did EcoR1 Capital Fund, Altitude Life Science Ventures, Baillie Gifford, Partner Fund Management (PFM), Pivotal Alpha, Invus Opportunities, Arch Venture Partners, Venrock, Founders Fund and Longevity Fund.
Unity Biotechnology is working on therapies…